Navigation Links
Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-Cancer Drug
Date:12/9/2010

EMERYVILLE, Calif., Dec. 9, 2010 /PRNewswire/ -- Angelica Therapeutics, Inc., a privately held drug development company focused on the development and commercialization of therapeutics incorporating novel nonimmunogenic fusion toxins, announced that it has received a $244,479 grant under the IRS Qualified Therapeutic Discovery Project Program. The grant is to advance the development of Angelica's lead drug candidate, Angeloxin, a fusion toxin consisting of deimmunized Diphtheria toxin (DT) fused to Interleukin-2 (IL2).  

The Qualified Therapeutic Discovery Project Program was part of the healthcare reform legislation enacted in March of this year and established a one-time pool of $1 billion for grants to small biotech companies developing novel therapeutics which show potential to, among other things, result in new therapies that either treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases and conditions or significantly advance the goal of curing cancer.  

Angelica has collaborated with Antitope, Ltd. (Cambridge, UK) to remove the T cell epitopes from Diphtheria toxin while retaining its cytotoxic potency.  Angeloxin, currently in preclinical development, is the most advanced drug candidate derived from Angelica's technology platform.  It promises to be an advance over Ontak®, currently marketed for the treatment of cutaneous T cell lymphoma and with reports of efficacy in other cancers as well, including peripheral T cell lymphoma and melanoma.

Geoff Davis, CEO of Angelica, said, "We are very pleased to see Angeloxin and the underlying technology platform recognized by this award.  We anticipate that our technology will constitute a significant advance in enabling repeated administration of highly potent and targeted drugs, even to immunocompetent patients, primarily for the treatment of cancer."

About Angelica Therapeutics, Inc. (www.angelicatherapeutics.com):  Angelica is a privately held biotechnology company focused on the development of "best in class" fusion toxins as therapeutics.   Angelica was founded in 2006 and has been funded solely by the founders and private investors.  The founders are Geoff Davis, Ph.D. (previously Chief Scientific Officer of Abgenix, Inc.), Thomas Tedder, Ph.D (Professor of Immunology, Duke University), and John Klacking, Ph.D. (a private investor).


'/>"/>
SOURCE Angelica Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
2. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
3. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
6. Halozyme Therapeutics Realigns Management
7. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
8. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
9. Nile Therapeutics Reports 2010 Third Quarter Financial Results
10. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. ImmunGenes Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... of $3,296 in property taxes a year. In some states—like New York, New ... , By contrast, many overseas retirement havens have extremely low property-tax rates, which ...
Breaking Medicine News(10 mins):